undamentalytics Newsletter
Sign in

Vir Biotechnology, Inc. cash flow statement

In fiscal 2025, Vir Biotechnology, Inc.'s operations generated −$392m of cash; it spent $4.8m on capital projects, leaving free cash flow of −$397m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−66−94−130−191−481,663−779−446−392−203
Depreciation and amortisation02345719151211
Stock-based pay5592884102111784947
Capital spending3897226822751
Free cash flow−69−102−139−197−691,595−800−454−397−204
Free cash flow after stock pay−74−107−147−225−1531,493−912−532−446−251
Shares issued——12632300————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: VCEL vs VIRADPT vs VIRARVN vs VIRSNDX vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vir Biotechnology, Inc.